Barry J. Gertz

7.5k citations

69 papers · 5.9k indexed · h-index 37

Pharmacology top 0.2%
- Inflammatory mediators and NSAID effects 22
- Pharmacogenetics and Drug Metabolism 10
Biochemistry top 0.5%
- Eicosanoids and Hypertension Pharmacology 8
Orthopedics and Sports Medicine top 1%
- Bone health and osteoporosis research 5
Pharmacology top 0.5%
- Inflammatory mediators and NSAID effects 22
- Pharmacogenetics and Drug Metabolism 10
Physiology top 2%
Cellular and Molecular Neuroscience
- Neuropeptides and Animal Physiology 8
Oncology
- Bone health and treatments 6
Molecular Biology
- Receptor Mechanisms and Signaling 5
Endocrinology, Diabetes and Metabolism
- Pituitary Gland Disorders and Treatments 4

Co-authors: Arturo G. Porras Sherry D. Holland Hui Quan Kenneth C. Lasseter Lee J. Martin Rhoda Sperling Alise Reicin Matthew R. Weir
Cited by: Pharmacology Biochemistry Orthopedics and Sports Medicine
Journals: New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (1 paper)Circulation (1 paper)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Barry J. Gertz

69 papers receiving 5.6k citations

Peers

Countries citing papers authored by Barry J. Gertz

Since Specialization

Citations

This map shows the geographic impact of Barry J. Gertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry J. Gertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry J. Gertz more than expected).

Fields of papers citing papers by Barry J. Gertz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry J. Gertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry J. Gertz. The network helps show where Barry J. Gertz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Barry J. Gertz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barry J. Gertz Line = papers co-authored together Barry J. Gertz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study Movement Disorders Clinical Practice ·Joseph Jankovic,Barbara J. Coffey,Daniel O. Claassen,Joohi Jimenez‐Shahed,Barry J. Gertz,Elizabeth A. Garofalo,David Stamler,Maria Wieman,Juha‐Matti Savola,Eran Harary,Jessica Alexander,Hadas Barkay,Mark Forrest Gordon	2023	7
2	152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents CNS Spectrums ·Joseph Jankovic,Barbara J. Coffey,Daniel O. Claassen,David Stamler,Barry J. Gertz,Elisabeth A. Garofalo,Maria Wieman,Mark Forrest Gordon,Juha‐Matti Savola	2020	1
3	The mitochondrial permeability transition pore in motor neurons: Involvement in the pathobiology of ALS mice Experimental Neurology ·Lee J. Martin,Barry J. Gertz,Yan Pan,Ann C. Price,Jeffery D. Molkentin,Qing Chang	2009	155
4	Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain Spine ·Nathaniel P. Katz,William D. Ju,David Krupa,Rhoda Sperling,Diana Bozalis Rodgers,Barry J. Gertz,Joseph Gimbel,Spencer Coleman,Chester Fisher,Shahriar Nabizadeh,David Borenstein	2003	45
5	Spine ·Nathaniel P. Katz,William Ju,David Krupa,Rhoda Sperling,Diana Bozalis Rodgers,Barry J. Gertz,Joseph Gimbel,Spencer Coleman,Chester F. Fisher,Shahriar Nabizadeh,David Borenstein,the Vioxx Chronic Low Back Pain Study Group	2003	1
6	Pharmacokinetic Evaluation of Rofecoxib Clinical Drug Investigation ·Jules I. Schwartz,Patrick Larson,Arturo G. Porras,Kala‐Jyoti Viswanathan‐Aiyer,Nancy Agrawal,Kenneth C. Lasseter,Ralph S. Mazenko,Sheila A. Merschman,Barry J. Gertz	2003	2
7	Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects The Journal of Clinical Pharmacology ·Jules I. Schwartz,Saurabh Mukhopadhyay,Arturo G. Porras,Kala‐Jyoti Viswanathan‐Aiyer,Sherilyn Adcock,David L. Ebel,Barry J. Gertz	2003	2
8	Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869 Cancer ·Simon Van Belle,M. Lichinitser,Rudolph M. Navari,August Garin,Marc Decramer,Alain Rivière,Myo Thant,Elmer Brestan,Binh Bui,Krista Eldridge,Marina De Smet,N. Michiels,Rick R. Reinhardt,Alexandra D. Carides,Judith K. Evans,Barry J. Gertz	2002	115
9	A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273] BMC Family Practice ·Eduardo Collantes‐Estévez,Sean Curtis,Ka Wing Lee,Noemí Casas,Tim McCarthy,Agustin Melian,Peng Zhao,Diana Bozalis Rodgers,Calogera L. McCormick,Michael Lee,Christopher R. Lines,Barry J. Gertz,(unknown)	2002	86
10	Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production Gastroenterology ·Nicholas J. Wight,Keith Gottesdiener,Nigel Garlick,Clare T. Atherton,Sue Novak,Barry J. Gertz,Nicole Calder,J Côté,Peggy Wong,A. Dallob,C J Hawkey	2001	49
11	Renal Effects of COX-2-Selective Inhibitors American Journal of Nephrology ·D. Craig Brater,Cynthia J. Harris,Jan S. Redfern,Barry J. Gertz	2001	191
12	Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity The Journal of Clinical Pharmacology ·Jacqueline B. McCrea,Thomayant Prueksaritanont,Barry J. Gertz,Alexandra D. Carides,Lisa Gillen,Suzanne Antonello,Mary Jo Brucker,Cynthia Miller‐Stein,Barbara A. Osborne,Scott A. Waldman	1999	49
13	Pharmacokinetics of Alendronate Clinical Pharmacokinetics ·Arturo G. Porras,Sherry D. Holland,Barry J. Gertz	1999	208
14	Effect of Obesity and Feeding on the Growth Hormone (GH) Response to the GH Secretagogue L-692,429 in Young Men¹ The Journal of Clinical Endocrinology & Metabolism ·Susan E. Kirk,Barry J. Gertz,Stephen H. Schneider,Mark L. Hartman,Suzan S. Pezzoli,Johanna Wittreich,David Krupa,James R. Seibold,Michael O. Thorner	1997	17
15	Initial human experience with MK-462 (rizatriptan): a novel 5=HT_IDagonist British Journal of Clinical Pharmacology ·David Sciberras,William J. Polvino,Barry J. Gertz,Haiyung Cheng,Michael Stepanavage,Johanna Wittreich,Timothy Olah,Mark Edwards,Timothy Mant	1997	28
16	Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults¹ The Journal of Clinical Endocrinology & Metabolism ·Ian Chapman,Ora Hirsch Pescovitz,Gail Murphy,Theresa Treep,K. Cerchio,David Krupa,Barry J. Gertz,William J. Polvino,Emily H. Skiles,Suzan S. Pezzoli,Michael O. Thorner	1997	49
17	The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans Clinical Pharmacology & Therapeutics ·M. Gail Murphy,Bozena Sytnik,Thomas O. Kovacs,Howard Mertz,Daria Ewanik,Sumiko Shingo,Juinn H. Lin,Barry J. Gertz,John H. Walsh	1993	27
18	Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist Biological Psychiatry ·Owen M. Wolkowitz,Barry J. Gertz,Herbert Weingartner,L Beccaria,Karen Thompson,Rodger A. Liddle	1990	50
19	Assessment of MK-912, an α2-adrenoceptor antagonist, with use of intravenous clonidine Clinical Pharmacology & Therapeutics ·J. B. Warren,C. T. Dollery,Richard W. Fuller,Vanessa C. Williams,Barry J. Gertz	1989	14
20	Clinical evaluation of a benzofuroquinolizine α2-adrenoceptor antagonist Clinical Pharmacology & Therapeutics ·Barry J. Gertz,Peter H. Vlasses,Mario L. Rocci,LISA D. COKER,Vanessa C. Williams,Thorir D. Bjornsson,Keith Jones	1989	4

About Barry J. Gertz

Barry J. Gertz is a scholar working on Pharmacology, Pharmacology and Biochemistry, having authored 69 papers that have together received 5.9k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (22 papers), Pharmacogenetics and Drug Metabolism (10 papers), Eicosanoids and Hypertension Pharmacology (8 papers), Neuropeptides and Animal Physiology (8 papers), Bone health and treatments (6 papers), Receptor Mechanisms and Signaling (5 papers), Bone health and osteoporosis research (5 papers) and Pituitary Gland Disorders and Treatments (4 papers). The work is most often cited by research in Pharmacology (1.9k citations), Biochemistry (630 citations) and Orthopedics and Sports Medicine (612 citations). Barry J. Gertz has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Arturo G. Porras, Sherry D. Holland, Hui Quan, Kenneth C. Lasseter, Lee J. Martin, Rhoda Sperling, Alise Reicin, Matthew R. Weir, D. Craig Brater and Briggs Morrison. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact